Comparing the current results to its competitors, In8bio Inc reported Revenue increase in the 2 quarter 2026 by 0 % year on year. The revenue growth was below In8bio Inc 's competitors' average revenue growth of 9.97 %, achieved in the same quarter.
In8bio Inc 's Comment on Competition and Industry Peers
The company operates in the competitive biotechnology industry, focusing on the development of proprietary gamma-delta T cell therapies. Its competitive position is supported by its gamma-delta T cell platform, product candidates, strategic collaborations, and scientific and clinical expertise. The company faces competition from larger pharmaceutical, specialty pharmaceutical, and biotechnology firms, as well as academic institutions, governmental agencies, and research organizations. Key factors influencing competition include efficacy, safety profile, pricing, administration method, and promotional activities. Competitors in the allogeneic and gamma-delta T cell therapy field include Acepodia USA, Adicet Bio, Inc., American Gene Technologies International Inc., Century Therapeutics, Inc., CytoMed Therapeutics Pte Ltd, Editas Medicine, Inc., and Enoch.
October 29, 2025
Expanding Horizons in Cancer Immunotherapy: IN8bio Welcomes The Ohio State University to the INB-100 Phase 1 Clinical Trial The pursuit of innovative cancer treatments takes another encouraging stride as IN8bio, a prominent biotechnology company focused on developing groundbreaking gamma-delta T cell therapies, has announced the expansion of its INB-100 Phase 1 clinical trial to include The Ohio State University as one of its trial sites. This significant development underscores the momentum and collaborative spirit driving forward promising new therapies in the fight against cancer.The INB-100 trial is designed to assess the safety and efficacy of IN8bio’s pioneering approach to cancer treatment utilizing...
August 12, 2024
Clinical Advancements in Gamma-Delta T Cell Therapy: IN8bio s Breakthroughs in OncologyRecent developments in the field of oncology have seen IN8bio, a leader in gamma-delta T cell therapy, make significant strides in the treatment of hematological malignancies and solid tumors. The company has reported promising results from its clinical trials, solidifying its position at the forefront of innovative cancer therapies.IN8bio announced groundbreaking results from the phase I study of its gamma-delta T cell therapy, INB-100, focusing on patients with acute myeloid leukemia (AML). Remarkably, the data reveals that 100% of treated AML patients have achieved complete remission, underscoring the potential effecti...
June 3, 2024
In recent groundbreaking presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and the American Association for Cancer Research (AACR) 2024, IN8bio, a leading biotechnology company, has showcased significant advancements in their Gamma-Delta T cell therapy platform. The company s findings demonstrate promising potential in the field of cancer treatment.During the ASGCT 2024 conference, IN8bio presented robust and reproducible manufacturing processes for their Gamma-Delta T cell therapy. The therapy offers immense promise in combating cancer due to its unique ability to harness the power of these specialized immune cells. With the goal of creating a more efficient and cost-effe...
November 20, 2023
IN8bios INB-200 Demonstrates Extended Progression-Free Survival in Patients with Newly Diagnosed Glioblastoma Glioblastoma (GBM) is an aggressive form of brain cancer with an incredibly poor prognosis. It is the most common malignant brain tumor in adults and is notoriously difficult to treat. However, a breakthrough has emerged in the form of an experimental drug known as INB-200, developed by the biopharmaceutical company IN8bios. In a recent press release, IN8bios revealed promising data on the efficacy of INB-200 in patients with newly diagnosed GBM. According to the release, all patients who completed the mandated doses of INB-200 demonstrated an unprecedented progression-free survival (PFS) of ...
Vir Biotechnology Inc is a clinical-stage immunology company that focuses on developing and commercializing innovative treatments for infectious diseases. Their business model revolves around the discovery and development of antibody therapies and other immunological approaches to combat a wide range of viral pathogens. They collaborate with leading research institutions and pharmaceutical companies to accelerate the development and commercialization of their products.
Moderna Inc's business model revolves around the development and commercialization of mRNA-based therapeutics and vaccines. They focus on using messenger RNA (mRNA) technology to create drugs that can help prevent and treat various diseases.
Molecular Partners Ag is a biotechnology company that operates on an innovative business model focused on the development of therapeutic drugs. The company utilizes its proprietary DARPin technology platform to create a pipeline of potential treatments for various diseases. Molecular Partners Ag primarily collaborates with strategic partners, including pharmaceutical companies, to advance its drug candidates through preclinical and clinical development stages.
Iovance Biotherapeutics Inc operates on a business model centered around developing and commercializing novel cancer immunotherapy treatments. The company focuses on utilizing its proprietary Tumor Infiltrating Lymphocyte (TIL) therapy, which involves collecting and expanding a patient's own immune cells to target and kill cancer cells. Iovance primarily seeks to advance its TIL therapy candidates through clinical trials and collaborations while aiming to provide effective and personalized treatment options for cancer patients.
Sources:
In8bio Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on In8bio Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
